About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
The Bottom Line
- HAP occurs >=48 hours after admission; VAP occurs >=48 hours after endotracheal intubation
- Common pathogens include Pseudomonas aeruginosa, MRSA, Enterobacterales, Acinetobacter, and other gram-negative bacilli
- Empiric therapy is based on mortality risk, MRSA risk, Pseudomonas risk, and local antibiogram
- Obtain respiratory cultures when possible and de-escalate antibiotics once results return
- VAP prevention: head-of-bed elevation, sedation minimization, daily extubation readiness, oral care, and avoiding unnecessary intubation
Overview
Hospital-acquired pneumonia and ventilator-associated pneumonia are major nosocomial infections with higher likelihood of multidrug-resistant organisms than community-acquired pneumonia. Diagnosis is clinical and radiographic: new or progressive infiltrate plus features such as fever, leukocytosis or leukopenia, purulent secretions, and worsening oxygenation. The IDSA/ATS guideline emphasizes local antibiograms, empiric coverage tailored to risk, and narrowing therapy to reduce resistance and toxicity.
Epidemiology
HAP and VAP are among the most common hospital-acquired infections in the United States and are associated with prolonged ICU stay, increased ventilator days, and increased mortality. VAP risk rises with duration of mechanical ventilation. Risk factors include intubation, aspiration, altered consciousness, supine position, prior IV antibiotics, severe underlying illness, immunosuppression, and structural lung disease.
Clinical Features
Symptoms
Fever or hypothermia after at least 48 hours in hospital or on ventilator
Purulent sputum or increased tracheal secretions
Worsening dyspnea or increased oxygen requirement
Pleuritic chest pain may occur in non-ventilated patients
Sepsis, shock, or altered mental status
Signs
New or progressive infiltrate on chest imaging
Leukocytosis or leukopenia
Worsening oxygenation, increased FiO2 requirement, or increased PEEP requirement
Crackles, bronchial breath sounds, or reduced breath sounds
Hemodynamic instability requiring vasopressors
Investigations
First-line
Chest X-rayNew or progressive infiltrate supports diagnosis but is not specific in ventilated patients
CBC, BMP, lactateAssess infection severity, renal function for antibiotic dosing, and sepsis physiology
Blood culturesRecommended in suspected VAP and selected HAP, especially severe disease or MRSA risk
Second-line
Respiratory cultureEndotracheal aspirate or sputum culture before antibiotics when feasible; use to de-escalate therapy
MRSA nasal PCRHigh negative predictive value in many settings; can support stopping vancomycin or linezolid if negative and clinical picture fits
Chest CTUse when diagnosis is unclear or complications such as abscess, empyema, or pulmonary embolism are considered
Specialist
Bronchoscopy with BALConsider if noninvasive cultures are inadequate, immunocompromised host, or alternative diagnosis is likely
ThoracentesisEvaluate significant pleural effusion for empyema or complicated parapneumonic effusion
1
Empiric treatment principles
- Start promptly after cultures in unstable patients; do not delay antibiotics for culture collection if shock is present
- Use local antibiogram and patient risk factors to choose empiric coverage
- Cover Staphylococcus aureus and Pseudomonas aeruginosa in most empiric regimens
- De-escalate once cultures and susceptibilities are available
- Typical duration is 7 days if clinical response is adequate
2
When to cover MRSA
- Prior IV antibiotics within 90 days
- Unit prevalence of MRSA is high or unknown
- High mortality risk, septic shock, or need for ventilatory support
- Use vancomycin or linezolid
3
Antipseudomonal therapy
- Options include cefepime, piperacillin-tazobactam, ceftazidime, aztreonam, meropenem, imipenem, levofloxacin, ciprofloxacin, or aminoglycoside-containing combinations depending on susceptibility
- Use two antipseudomonal agents from different classes when high mortality risk or resistant gram-negative infection risk is present
- Avoid aminoglycoside monotherapy because lung penetration is poor
4
Prevention and supportive care
- Elevate head of bed 30-45 degrees
- Daily sedation interruption and spontaneous breathing trials when appropriate
- Oral care and aspiration precautions
- Use noninvasive ventilation or high-flow oxygen when appropriate to avoid intubation
Complications
- Septic shock: Vasopressor requirement and organ dysfunction increase mortality
- ARDS: Diffuse inflammatory lung injury can follow severe bacterial pneumonia
- Empyema: Pleural infection requires drainage plus antibiotics
- Lung abscess: Necrotizing pneumonia may cavitate and require prolonged therapy
- Multidrug resistance: Broad-spectrum exposure increases risk of resistant gram-negative organisms and C difficile infection
USMLE Step 2 CK Exam Tips
- 1HAP = pneumonia after >=48 hours in hospital; VAP = after >=48 hours of intubation
- 2VAP stem: ventilated ICU patient with fever, purulent secretions, new infiltrate, and increased oxygen requirement
- 3Empiric VAP therapy usually needs antipseudomonal coverage; add MRSA coverage when risk factors exist
- 4Vancomycin and linezolid are the MRSA options tested most often
- 5Use culture results to de-escalate; continuing broad therapy despite susceptibility data is wrong
- 6Aminoglycosides should not be used as monotherapy for pneumonia
- 7Head-of-bed elevation and daily spontaneous breathing trials reduce VAP risk
practicetest your knowledge on hospital-acquired / ventilator-associated pneumoniaApply what you've learnt with USMLE Step 2 CK-style questions from the iatroX Q-Bank — respiratory and beyond.
open q-bank